<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0035-0052</journal-id>
<journal-title><![CDATA[Revista mexicana de pediatría]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. pediatr.]]></abbrev-journal-title>
<issn>0035-0052</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Pediatría A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0035-00522024000600222</article-id>
<article-id pub-id-type="doi">10.35366/120537</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores de riesgo asociados a nefrotoxicidad por cisplatino en pacientes con cáncer]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk factors associated with cisplatin nephrotoxicity in cancer patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maceda-Nazario]]></surname>
<given-names><![CDATA[Nancy Delia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zurita-Cruz]]></surname>
<given-names><![CDATA[Jessie N]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zepeda-Martínez]]></surname>
<given-names><![CDATA[Claudia del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alegría-Torres]]></surname>
<given-names><![CDATA[Gabriela Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Betanzos-Cabrera]]></surname>
<given-names><![CDATA[Yadira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI Unidad Médica de Alta Especialidad Hospital de Pediatría]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI Hospital de Pediatría]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>91</volume>
<numero>6</numero>
<fpage>222</fpage>
<lpage>227</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0035-00522024000600222&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0035-00522024000600222&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0035-00522024000600222&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La nefrotoxicidad asociada al uso de cisplatino está relacionada principalmente con la acumulación de metabolitos en las células del túbulo renal proximal.  Objetivo:  Identificar factores de riesgo asociados a nefrotoxicidad en pacientes pediátricos con cáncer que reciben cisplatino.  Material y métodos:  Estudio de cohorte retrospectivo. Se incluyeron pacientes con tumores sólidos, atendidos entre 2015 y 2021, que recibieron cisplatino como parte del tratamiento oncológico. A todos se siguieron hasta completar el esquema de cisplatino. Se registraron datos clínicos y de laboratorio. De cada ciclo de quimioterapia se documentó el uso de sulfato de magnesio, administración de nefrotóxicos, dosis acumulada de cisplatino y cambios en la función renal (creatinina y tasa de filtrado glomerular [TFG]). La nefrotoxicidad se definió como el aumento de la creatinina sérica &gt; 0.5 mg/dL, respecto al valor inicial.  Análisis estadístico: La comparación entre grupos fue con las pruebas &#967;2, exacta de Fisher y U Mann-Whitney. El control de las variables de confusión fue con riesgos proporcionales de Cox.  Resultados:  Se estudiaron 101 pacientes; la mediana de edad fue de 11 años y el 62.4% fueron varones. La mediana de creatinina sérica aumentó al final de la vigilancia de 0.47 mg/dL a 0.72 mg/dL, mientras la TFG descendió de 120 a 82 mL/min/1.73 m2. El 23.8% desarrolló nefrotoxicidad, y 14.8% tubulopatía. La administración de sulfato de magnesio (HR 0.233; IC95% 0.926-0.587; p = 0.002) y mayores niveles de fósforo sérico antes del inicio de la quimioterapia (HR 0.529; IC95% 0.315-0.888; p = 0.016) resultaron como protectores de esta complicación.  Conclusiones:  En pacientes pediátricos con cáncer, la frecuencia de nefrotoxicidad por cisplatino es de alrededor del 20%. La administración de sulfato de magnesio y las mayores concentraciones séricas de fósforo son factores protectores para el desarrollo de nefrotoxicidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Cisplatin-associated nephrotoxicity is primarily related to the accumulation of metabolites in proximal renal tubule cells.  Objective:  To identify risk factors associated with nephrotoxicity in pediatric cancer patients who received cisplatin.  Material and methods:  Retrospective cohort study. Patients with solid tumors treated between 2015 and 2021 who received cisplatin as part of their oncological treatment were included. All were followed until they completed the cisplatin regimen. Clinical and laboratory data were recorded. Magnesium sulfate use, nephrotoxic administration, cumulative cisplatin dose, and changes in renal function (creatinine and glomerular filtration rate [GFR]) were documented for each chemotherapy cycle. Nephrotoxicity was defined as an increase in serum creatinine &gt; 0.5 mg/dL from baseline.  Statistical analysis: Comparisons between groups were made using the &#967;2, Fisher&#8217;s exact, and Mann-Whitney U tests. Control of confounding variables was with Cox proportional hazards (HR).  Results:  A total of 101 patients were studied; the median age was 11 years, and 62.4% were men. Median serum creatinine increased from 0.47 mg/dL to 0.72 mg/dL at the end of surveillance, while GFR decreased from 120 to 82 mL/min/1.73 m2. Nephrotoxicity was present in 23.8% of patients, and tubulopathy in 14.8%. Magnesium sulfate administration (HR 0.233; 95% CI 0.926-0.587; p = 0.002) and higher serum phosphorus levels before the start of chemotherapy (HR 0.529; 95% CI 0.315-0.888; p = 0.016) were determined as protectors for this complication.  Conclusions:  In pediatric cancer patients, the incidence of cisplatin-induced nephrotoxicity is approximately 20%. The administration of magnesium sulfate and higher serum phosphorus concentrations are protective factors for the development of nephrotoxicity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[nefrotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[cisplatino]]></kwd>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[pediatría]]></kwd>
<kwd lng="es"><![CDATA[sulfato de magnesio]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="en"><![CDATA[nephrotoxicity]]></kwd>
<kwd lng="en"><![CDATA[cisplatin]]></kwd>
<kwd lng="en"><![CDATA[cancer]]></kwd>
<kwd lng="en"><![CDATA[pediatrics]]></kwd>
<kwd lng="en"><![CDATA[magnesium sulfate]]></kwd>
<kwd lng="en"><![CDATA[risk factors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LaQuaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstle]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the treatment of pediatric solid tumors: a 50-year perspective]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2022</year>
<volume>126</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>933-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[DeSantis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kohler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Childhood and adolescent cancer statistics, 2014]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2014</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>83-103</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papakonstantinou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Athanasiadou]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Markozannes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tzotzola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bouka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in high-grade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Cancer Epidemiol]]></source>
<year>2024</year>
<volume>90</volume>
<page-range>102551</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cisplatin: the first metal based anticancer drug]]></article-title>
<source><![CDATA[Bioorg Chem]]></source>
<year>2019</year>
<volume>88</volume>
<page-range>102925</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dasari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tchounwou]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cisplatin in cancer therapy: molecular mechanisms of action]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2014</year>
<volume>740</volume>
<page-range>364-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rancoule]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guy]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Vallard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Mrad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rehailia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Magné]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Les 50 ans du cisplatine [50th anniversary of cisplatin]]]></article-title>
<source><![CDATA[Bull Cancer]]></source>
<year>2017</year>
<volume>104</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McSweeney]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Gadanec]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Qaradakhi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Zulli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Apostolopoulos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2021</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1572</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malyszko]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tesarova]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Capasso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Capasso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The link between kidney disease and cancer: complications and treatment]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<numero>10246</numero>
<issue>10246</issue>
<page-range>277-87</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caglar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kinalp]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arpaci]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Turan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saglam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ozturk]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2002</year>
<volume>17</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1931-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crona]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Faso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nishijima]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[McGraw]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Galsky]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Milowsky]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of strategies to prevent cisplatin-induced nephrotoxicity]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2017</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>609-19</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rohatgi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nephrotoxicity: evidence in patients receiving cisplatin therapy]]></article-title>
<source><![CDATA[Clin J Oncol Nurs]]></source>
<year>2018</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>175-83</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyoshi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uoi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omura]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tsumagari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maesaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yokota]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study]]></article-title>
<source><![CDATA[Oncology]]></source>
<year>2021</year>
<volume>99</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-13</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volarevic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Djokovic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Harrell]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Fellabaum]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Djonov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity]]></article-title>
<source><![CDATA[J Biomed Sci]]></source>
<year>2019</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyoshi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uoi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omura]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tsumagari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Maesaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preventive effect of 20 mEq and 8 mEq magnesium supplmentation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2022</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>3345-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
